undamentalytics Newsletter
Sign in

Tango Therapeutics, Inc. (TNGX) stock

Add to watchlist

Add holding +

NASDAQ: TNGX Nasdaq Biotechnology Next results ~November 4, 2026

C Fundamentals grade

Tango Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Tango Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 4 selling0 purchases and 25 sales by directors and officers, last 12 monthsInsider trades
  • Funds171 adding, 77 cuttingOf 66 active managers that changed their stake, 40 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Tango Therapeutics files

Where Tango Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $54m, up 121.5% on a year earlier, faster than the 39.0% growth a quarter earlier. That growth ranks 25 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -268.1% from -613.9% a year earlier. Operating margin widened to -253.4% from -647.3%. The diluted share count is up 21.8% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks.

Our model value for Tango Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Tango Therapeutics, Inc.'s trailing-twelve-month revenue grew 121.5% year on year, with a free-cash-flow margin of -268.1%. Where it stands out: change in growth rate of +82.4pp ranks 21 of 172 biotechnology companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 351% year over year while revenue grew 121% — the balance sheet is expanding 230 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 121.5% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 82.4 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 394.0 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.3bn.

Things to watch

  • Loss-making. Operating margin is -253.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -268.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 74.9% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 21.8% in a year.
  • High sales multiple. The shares trade at 54 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 100% and a beta of 1.3 against the S&P 500.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.37 against an average estimate of -$0.32: missed by 14.2%
Share reaction
-7.6% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$0.35

Tango Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+7.9%
  • 1 week+2.6%
  • 1 month+1.0%
  • This year+145.6%
  • 1 year+193.1%
  • 5 years+83.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$53.8M
Operating margin
-253.4%
Net margin
-229.9%
EPS (TTM, diluted)
$-0.92

Growth

Revenue growth
+121.5%
Change in growth rate
+82.4 pts
Share count change
+21.8%

Cash

Free cash flow (TTM)
-$144M
FCF margin
-268.1%
Stock pay % of revenue
74.9%

Earnings

Last results
August 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Results
  4. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Tango Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Tango Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.7%: the 10-year Treasury yield (4.9%) plus a beta of 0.82 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.1 Left out: out of range vs price (0.01x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 ~$0.1–$0.2 Left out: out of range vs price (0.00x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Tango Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$11.44$10.94$7.25$9.90$3.09$8.86$21.76
Market value$731m$679m$637m$936m$338m$1.0bn$2.9bn
+ Net debt (− = net cash)−$28m−$143m−$60m−$66m−$70m−$112m−$346m
Enterprise value$702m$537m$577m$870m$268m$917m$2.6bn
Multiples
Price / sales 95.4x18.3x25.6x25.6x8.0x16.5x54.3x
Price / earnings ———————
Price / free cash flow 10.6x——————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Tango Therapeutics's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -27.1% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -325.0%; its worst year was -647.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -334.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.35 (range −$0.42 to −$0.30) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.40 −60% — −100%
Next −$1.69 −21% $3m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +7.8% on 90 days ago. In the last 30 days, 0 analysts raised Tango Therapeutics, Inc.'s forecast and 3 cut it.

Consensus EPS forecast Tango Therapeutics, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.29 Current fiscal year, 60 days ago: −$1.38 Current fiscal year, 30 days ago: −$1.40 Current fiscal year, 7 days ago: −$1.40 Current fiscal year, Now: −$1.40 −$1.40 Next fiscal year, 90 days ago: −$1.52 Next fiscal year, 60 days ago: −$1.63 Next fiscal year, 30 days ago: −$1.69 Next fiscal year, 7 days ago: −$1.66 Next fiscal year, Now: −$1.69 −$1.69

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.29−$1.52
60 days ago −$1.38−$1.63
30 days ago −$1.40−$1.69
7 days ago −$1.40−$1.66
Now −$1.40−$1.69

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.32 −$0.37 −14.2%
Mar 2026 −$0.31 −$0.32 −1.7%
Dec 2025 −$0.33 −$0.29 +11.8%
Sept 2025 −$0.07 $0.13 +287.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

13 analysts, Oct 2026
Buy1292%
Hold18%
Sell00%

Monthly trend

  1. Oct 2026111113
  2. Sep 2026110112
  3. Aug 2026111113
  4. Jul 2026111113

Counts of recommendations published by analysts covering Tango Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
26.9%
of tradable shares
Days to cover
11.9
at average volume
Short interest, 1 month
+7%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.2%
of shares
Employees
137
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +168.3%

$8.11 on October 31, 2025 to $21.76

ThenNowEffect
Revenue (last 12 months) $24m $54m +121.5%
P/S multiple 36.8x 54.3x +47.5%
Share count 110m 134m −17.9%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TNGX−4%−34%+37%−69%+187%+146%
Industry peers (median)−36%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TNGX50%25%42%33%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TNGX−45%−70%−67%−78%−68%−34%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since September 3, 2020: 94% from September 17, 2021 to May 8, 2025. Getting back needed a 1473% gain, reached on March 13, 2026, 309 days after the low.

Price behaviour

52-week range
$7.51 – $32.90
From 52-week high
−33.9%
vs 50-day average
−7.6%
vs 200-day average
−2.8%
Volatility (1 year)
101%
Beta vs S&P 500
1.34

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±13.6%
After a week
6 up, 6 down
typical move ±18.6%
After a month
8 up, 4 down
typical move ±49.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 −7.6% −0.1% −8.1% −15.5%
May 13, 2026 +5.8% +1.4% −10.3% +31.7%
March 5, 2026 +37.2% −1.9% +38.9% +64.3%
January 8, 2026 −0.3% +0.7% −0.8% +9.3%
November 4, 2025 −6.2% −0.8% +4.6% +23.6%
October 23, 2025 −13.5% +1.4% −8.0% +15.8%
August 5, 2025 −1.4% +0.3% +2.6% +3.6%
May 12, 2025 +22.8% +4.0% +100.9% +315.8%
February 27, 2025 −11.2% −0.1% −9.4% −36.9%
January 13, 2025 −10.4% +0.3% +5.3% −15.9%
November 6, 2024 −45.4% +3.3% −31.3% −34.7%
August 7, 2024 −1.1% +1.6% +3.2% +20.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Tango Therapeutics, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Tango Therapeutics, Inc.
$20M $40M $60M $80M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $37.5M Revenue (TTM), FY23 Q4: $36.5M Revenue (TTM), FY24 Q1: $37.2M Revenue (TTM), FY24 Q2: $42.5M Revenue (TTM), FY24 Q3: $43.4M Revenue (TTM), FY24 Q4: $42.1M Revenue (TTM), FY25 Q1: $41M Revenue (TTM), FY25 Q2: $24.3M Revenue (TTM), FY25 Q3: $66.5M Revenue (TTM), FY25 Q4: $62.4M Revenue (TTM), FY26 Q1: $57M Revenue (TTM), FY26 Q2: $53.8M $53.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $37.5M
FY23 Q4 $36.5M
FY24 Q1 $37.2M
FY24 Q2 $42.5M
FY24 Q3 $43.4M
FY24 Q4 $42.1M
FY25 Q1 $41M
FY25 Q2 $24.3M
FY25 Q3 $66.5M
FY25 Q4 $62.4M
FY26 Q1 $57M
FY26 Q2 $53.8M
Revenue growth, TTM YoY Tango Therapeutics, Inc.
-50% 0% 50% 100% 150% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 55.2% Revenue growth, TTM YoY, FY23 Q4: 46.9% Revenue growth, TTM YoY, FY24 Q1: 49.7% Revenue growth, TTM YoY, FY24 Q2: 26.2% Revenue growth, TTM YoY, FY24 Q3: 15.7% Revenue growth, TTM YoY, FY24 Q4: 15.2% Revenue growth, TTM YoY, FY25 Q1: 10.1% Revenue growth, TTM YoY, FY25 Q2: -42.8% Revenue growth, TTM YoY, FY25 Q3: 53.3% Revenue growth, TTM YoY, FY25 Q4: 48.3% Revenue growth, TTM YoY, FY26 Q1: 39.0% Revenue growth, TTM YoY, FY26 Q2: 121.5% 121.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 55.2%
FY23 Q4 46.9%
FY24 Q1 49.7%
FY24 Q2 26.2%
FY24 Q3 15.7%
FY24 Q4 15.2%
FY25 Q1 10.1%
FY25 Q2 -42.8%
FY25 Q3 53.3%
FY25 Q4 48.3%
FY26 Q1 39.0%
FY26 Q2 121.5%
Operating margin (TTM) Tango Therapeutics, Inc.
-800% -600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -292.5% Operating margin (TTM), FY23 Q4: -312.6% Operating margin (TTM), FY24 Q1: -338.8% Operating margin (TTM), FY24 Q2: -311.6% Operating margin (TTM), FY24 Q3: -322.0% Operating margin (TTM), FY24 Q4: -346.1% Operating margin (TTM), FY25 Q1: -355.9% Operating margin (TTM), FY25 Q2: -647.3% Operating margin (TTM), FY25 Q3: -165.9% Operating margin (TTM), FY25 Q4: -178.4% Operating margin (TTM), FY26 Q1: -206.2% Operating margin (TTM), FY26 Q2: -253.4% -253.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -292.5%
FY23 Q4 -312.6%
FY24 Q1 -338.8%
FY24 Q2 -311.6%
FY24 Q3 -322.0%
FY24 Q4 -346.1%
FY25 Q1 -355.9%
FY25 Q2 -647.3%
FY25 Q3 -165.9%
FY25 Q4 -178.4%
FY26 Q1 -206.2%
FY26 Q2 -253.4%
FCF margin (TTM) Tango Therapeutics, Inc.
-800% -600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -322.9% FCF margin (TTM), FY23 Q4: -327.2% FCF margin (TTM), FY24 Q1: -327.8% FCF margin (TTM), FY24 Q2: -284.2% FCF margin (TTM), FY24 Q3: -283.9% FCF margin (TTM), FY24 Q4: -314.4% FCF margin (TTM), FY25 Q1: -331.7% FCF margin (TTM), FY25 Q2: -613.9% FCF margin (TTM), FY25 Q3: -220.7% FCF margin (TTM), FY25 Q4: -224.3% FCF margin (TTM), FY26 Q1: -250.1% FCF margin (TTM), FY26 Q2: -268.1% -268.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -322.9%
FY23 Q4 -327.2%
FY24 Q1 -327.8%
FY24 Q2 -284.2%
FY24 Q3 -283.9%
FY24 Q4 -314.4%
FY25 Q1 -331.7%
FY25 Q2 -613.9%
FY25 Q3 -220.7%
FY25 Q4 -224.3%
FY26 Q1 -250.1%
FY26 Q2 -268.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 8 37 25 37 42 62 54
EBITDA −51 −57 −109 −112 −143 −109 −134
Operating income −52 −58 −111 −114 −146 −111 −136
Net income −52 −58 −108 −102 −130 −102 −124
Diluted EPS −$0.81 −$0.94 −$1.23 −$1.08 −$1.19 −$0.87 −$0.92
Growth (year on year)
Revenue — +383.8% −32.9% +46.9% +15.2% +48.3% +121.5%
Margins
EBITDA margin −672.4% −154.7% −440.3% −306.0% −340.1% −174.7% −249.8%
Operating margin −681.8% −157.1% −446.8% −312.6% −346.1% −178.4% −253.4%
Net margin −678.8% −157.2% −435.1% −278.5% −309.7% −162.9% −229.9%
Free-cash-flow margin 900.8% −165.7% −469.7% −327.2% −314.4% −224.3% −268.1%
Cash flow
Cash from operations 70 −60 −109 −118 −132 −139 −144
Capital spending 1 2 8 2 1 1 0
Free cash flow 69 −61 −117 −120 −132 −140 −144
Stock-based pay 2 8 14 19 29 26 40
Free cash flow after stock pay 67 −69 −131 −139 −161 −166 −185
Balance sheet
Cash 28 143 60 66 70 112 346
Total debt 0 0 0 0 0 0 0
Net debt (negative = net cash) −28 −143 −60 −66 −70 −112 −346
Diluted shares 64m 62m 88m 95m 109m 116m 134m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.1bn
Short-term assets $1.0bnLonger-term assets $42m
What it owes, and who funded it · $1.1bn
Short-term liabilities $20mLonger-term liabilities $29mShareholders' equity $1.0bn
  • Short-term assets cover short-term liabilities $1.0bn of assets due within a year against $20m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.0bn short-term assets against $29m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Tango Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+21.8%
year over year
R&D spending
248.4%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated TNGX SIGA GOSS NKTR OCUL IVVD Median
Revenue, last 12 months $54m $54m $53m $55m $52m $58m $56m
Revenue growth, last 12 months 121.5% −70.1% 32.4% −27.2% −8.1% 26.3% 12.6%
Revenue growth, 3-year average 16.9% −18.1% — −14.6% −1.6% — 13.7%
Revenue growth, latest quarter −100.0% −49.5% −19.6% −9.3% 0.1% 21.2% 10.2%
Gross margin — 54.4% — 100.0% 87.1% — 82.9%
Operating margin −253.4% −20.8% −311.7% −257.8% −603.0% −192.8% −189.4%
Operating margin, 3-year average −404.1% 31.6% −252.1% −189.3% −397.7% <−999% −363.5%
Net margin −229.9% −5.2% −235.0% −287.8% −579.1% −183.9% −169.8%
Cash from operations / revenue −267.4% −37.6% −305.2% −428.3% −457.7% −185.8% −168.0%
Free-cash-flow margin −268.1% −38.2% −305.2% −428.7% −490.1% −187.9% −162.4%
Free-cash-flow margin, 3-year average −388.7% 23.6% −231.0% −288.4% −318.3% <−999% −310.0%
Stock pay / revenue 74.9% 6.5% 26.9% 22.0% 102.4% 19.2% 20.0%
Change in share count 21.8% 0.1% 14.3% 6.2% 26.4% 14.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 121.5% 12.6% 36 of 172
Change in growth rate Growth +82.4pp -0.1pp 21 of 172
Operating margin Profitability -253.4% -189.4% 97 of 175
Net margin Profitability -229.9% -157.3% 99 of 180
Free-cash-flow margin Cash generation -268.1% -145.4% 110 of 176
Stock pay as % of revenue Cash generation 74.9% 19.2% 129 of 179
Change in share count Balance sheet 21.8% 7.9% 117 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$6.6B
Institutions reporting
245
Shares held vs prior quarter
▲ 19.0%
Positions opened / closed
71 / 22

Top buyers and sellers, Q2 2026: 171 institutions bought and 77 sold ; the biggest buyer was Price T Rowe Associates Inc (+5.5M shares) and the biggest seller Nextech Invest Ltd (−7.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RTW Investments, LP $435M 13.9M 6.6% ▲ 4.5%
Blackrock, Inc. $389M 12.4M 5.9% ▲ 42.2%
FMR LLC $386M 12.3M 5.8% ▲ 24.5%
Farallon Capital Management, L.L.C. $384M 12.3M 5.8% ▲ 35.0%
Boxer Capital Management, LLC $340M 10.9M 5.1% 0.0%
Goldman Sachs Group Inc $312M 10.0M 4.7% ▲ 96.6%
Tcg Crossover Management, LLC $284M 9.1M 4.3% ▼ 13.8%
Paradigm Biocapital Advisors LP $199M 6.4M 3.0% ▲ 58.6%
Price T Rowe Associates Inc $198M 6.3M 3.0% ▲ 613.8%
Siren, L.L.C. $193M 6.2M 2.9% ▲ 9.2%
State Street Corp $187M 6.0M 2.8% ▲ 28.5%
Vanguard Capital Management LLC $186M 6.0M 2.8% ▲ 15.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Tango Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $7.7M 25 trades by 4 insiders · 91% under pre-set plans
Net ▼ $7.7M net selling
Insider Date Trade Shares Price Value
Crystal Adam President, R&D October 1, 2026 Sell pre-set plan 600 $25.32 $15,192
Crystal Adam President, R&D October 1, 2026 Sell pre-set plan 26,400 $24.45 $645,604
Newcomb Jessica Principal Accounting Officer September 22, 2026 Sell pre-set plan 700 $22.80 $15,960
Newcomb Jessica Principal Accounting Officer September 22, 2026 Sell pre-set plan 5,100 $23.97 $122,247
Newcomb Jessica Principal Accounting Officer September 22, 2026 Sell pre-set plan 2,400 $25.17 $60,408
Crystal Adam President, R&D September 1, 2026 Sell pre-set plan 27,000 $22.37 $603,990
Crystal Adam President, R&D August 3, 2026 Sell pre-set plan 5,267 $26.79 $141,103
Crystal Adam President, R&D August 3, 2026 Sell pre-set plan 21,733 $27.35 $594,398
Crystal Adam President, R&D July 1, 2026 Sell pre-set plan 19,629 $29.34 $575,915
Crystal Adam President, R&D July 1, 2026 Sell pre-set plan 7,371 $30.25 $222,973
Crystal Adam President, R&D June 1, 2026 Sell pre-set plan 6,140 $22.25 $136,615
Crystal Adam President, R&D June 1, 2026 Sell pre-set plan 20,860 $23.06 $481,032

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 22, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 13, 2026
  • March 5, 2026
  • January 8, 2026
  • November 4, 2025
  • October 23, 2025

Recent SEC filings

Data status

When each part of this page on Tango Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Tango Therapeutics, Inc. in brief

What does Tango Therapeutics, Inc. do?
Tango Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Tango Therapeutics, Inc.'s stock ticker?
Tango Therapeutics, Inc. trades under the ticker TNGX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Tango Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Tango Therapeutics, Inc. reported revenue of $53.8M, 121.5% higher than a year earlier, according to its SEC filings.
What is Tango Therapeutics, Inc.'s free cash flow?
Tango Therapeutics, Inc.'s free-cash-flow margin is -268.1% of revenue over the trailing twelve months, ranking 110 of the 176 biotechnology companies we cover.
Who are Tango Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RTW Investments, LP, Blackrock, Inc. and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Tango Therapeutics, Inc.'s market cap?
On November 2, 2026, Tango Therapeutics, Inc.'s market capitalisation was about $2.9B and net debt of -$346M. Market figures come from third-party market data and may be delayed.
Who are Tango Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Tango Therapeutics, Inc. are Siga Technologies Inc, Gossamer Bio, Inc., Nektar Therapeutics, Ocular Therapeutix, Inc and Invivyd, Inc. The side-by-side comparison below sets their revenue, margins and growth against Tango Therapeutics, Inc.'s.
Are insiders buying or selling Tango Therapeutics, Inc. stock?
Over the last 12 months, Tango Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 25 sales on Form 4. The insider trading page charts every trade.
When is Tango Therapeutics, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Tango Therapeutics, Inc. announces its own schedule.